Form 4: Candel Therapeutics Director Gary Nabel Acquires Over 5,000 Shares in Direct Offering

Candel Therapeutics, Inc. Director Gary J. Nabel has acquired 5,353 shares of common stock at $4.67 per share through a registered direct offering.

Summary

• Gary J. Nabel, a Director of Candel Therapeutics, Inc. (CADL), acquired 5,353 shares of common stock.
• The acquisition occurred on June 25, 2025, at a price of $4.67 per share.
• The shares were acquired directly from the Issuer as part of a registered direct offering.
• This transaction was conducted pursuant to a Securities Purchase Agreement dated June 23, 2025.
• Following this transaction, Mr. Nabel directly beneficially owns 5,353 shares of Candel Therapeutics common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is generally a positive indicator, suggesting confidence in the company's prospects. However, the context of a direct offering implies capital needs, which can be a mixed signal depending on the use of proceeds and terms.

Positives

• Insider buying by a Director (Gary J. Nabel) signals confidence in the company's future prospects.
• The acquisition was made at a specific price of $4.67 per share, indicating a valuation point for the insider.

Negatives

• The acquisition was part of a "registered direct offering," which typically involves the issuance of new shares, potentially leading to dilution for existing shareholders.

Future Outlook

NA

Industry Context

This insider acquisition by a director of Candel Therapeutics, a biotechnology company, is a common event in the industry. Insider buying can be interpreted as a sign of confidence in the company's drug pipeline or strategic direction, especially following a capital raise.

Related Party Transactions

• Director Gary J. Nabel acquired shares directly from Candel Therapeutics, Inc. as part of a registered direct offering, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The direct offering likely resulted in dilution of existing shares, but the insider purchase may instill confidence in the company's future.
• Company: The direct offering provides capital to the company, which can be used for operations, research, or other strategic initiatives.

Key Dates

Keywords

Candel Therapeutics, CADL, Gary J. Nabel, Insider Trading, Form 4, Share Acquisition, Direct Offering, Common Stock, Director